Objective       To investigate the role of special inhibitor of NF-κB pathway

pyrrolidine dithiocarbamate (PDTC)

in wound healing by transplanting bone marrow mesenchymal stem cells (MSCs) in STZ-reduced diabetic mice.       Methods       The bone marrow MSCs from GFP transgenic mice were iso

lated and cultured. For C57BL/6 mice

diabetes was induced by multiple low-dose of STZ (50 mg/kg injection i.p

once a day for 5 consecutive days). A round dorsal skin defect

in a diameter of 6 mm

was made in the mice model. The experimental animals were divided into 4 groups

that is

normal control

diabetic control group

MSCs treatment group (receiving 2.5×10

5

MSCs per dose in 8 areas surrounding wound margin)

MSCs+PDTC group (receiving 2.5×10

5

MSCs and injection i.p of PDTC). Wound healing was observed in 3

7

11

and 14 d after operation

and wound tissue was cut and observed by HE staining and immunohistochemical assay.        Results       The wound healing rate was significantly higher in MSCs+PDTC group than in MSCs treatment group and diabetic control group（

P

<

0.05）. HE staining indicated that there was better vascular formation in the former than the 2 later groups. Immunohistochemical assay showed VEGF was expressed in MSCs+PDTC group (33.51±2.40) in 11 d after operation

significantly strongly than those in MSCs treatment group (18.71±7.14) and diabetic control group（26.07±4.50

P

<

0.05). While the expression of NF-kappa B expression was significantly reduced in MSCs+PDTC group （35.20±18.77）than in MSCs treatment group （56.80±16.35）and diabetic control group（130.64±16.35

P

<

0.05）. On the 14th day

GFP fluorescence signal was significantly stronger in MSCs+PDTC group（135.20±11.84） than in MSCs treatment group （46.81±22.37

P

<

0.05).       Conclusion       PDTC could promote wound healing in diabetic mice treated with bone marrow MSCs by blocking NF-kappaB pathway.